CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

CRISPR Therapeutics already has Casgevy on the market, but hopes its two in-vivo gene-editing cardiovascular drugs can reach a broader market.

More from Clinical Trials

More from Therapy Areas